{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.6","upperLimit":"9.6","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"The observed length of life from entry into the study to death or the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.","id":"OG000","title":"Thalidomide"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"From study entry to death or last contact, up to 5 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}